SCHEMBL20639833

SCHEMBL20639833

O=C(c1cc(F)ccc1F)C(F)(F)c1ccc(Br)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 3/20 0.42
▸ CES1 P23141 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ GRK2 P25098 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.34
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ GRM5 P41594 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ DGAT1 O75907 1/20 0.33
▸ DGAT2 Q96PD7 1/20 0.32
▸ P2RX7 Q99572 1/20 0.32
▸ PPARD Q03181 1/20 0.32
▸ CDK5 Q00535 1/20 0.32
▸ CDK5R1 Q15078 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30352878 0.89 CES2 (0.42) CES2CES1ALDH1A1L3MBTL1POLB
SCHEMBL2554655 0.89 CES2 (0.42) CES2CES1ALDH1A1L3MBTL1POLB
SCHEMBL30270028 0.83 KAT6A (0.43) CES2CES1ALDH1A1KDM4ETP53
SCHEMBL20640043 0.83 KAT6A (0.43) CES2CES1ALDH1A1KDM4ETP53
SCHEMBL20639929 0.80 GRM5 (0.40) CES2CES1ALDH1A1L3MBTL1POLB
SCHEMBL17119708 0.79 DGAT1 (0.37) ALDH1A1L3MBTL1KDM4EMAPTATM
SCHEMBL30270081 0.78 CES2 (0.42) CES2CES1ALDH1A1POLBRXFP1
SCHEMBL20639969 0.78 CES2 (0.42) CES2CES1ALDH1A1POLBRXFP1
SCHEMBL14405776 0.76 CES2 (0.41) CES2CES1ALDH1A1L3MBTL1KDM4E
SCHEMBL14332118 0.76 CYP3A4 (0.43) CES2CES1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3397629-B1 METALLOENZYME INHIBITOR COMPOUNDS NQP 1598 LTD (KY) 2023-04-19 — — EP disclosed
EP-3397629-B1 METALLOENZYME INHIBITOR COMPOUNDS NQP 1598 LTD (KY) 2023-04-19 — — EP disclosed
CN-108779094-B Metalloenzyme inhibitor compounds NQP 1598公司 2021-11-16 — — CN disclosed
US-10464922-B2 Metalloenzyme inhibitor compounds NQP 1598, LTD. (US) 2019-11-05 — — US disclosed
US-10464922-B2 Metalloenzyme inhibitor compounds NQP 1598, LTD. (US) 2019-11-05 — — US disclosed
US-20190016700-A1 METALLOENZYME INHIBITOR COMPOUNDS NQP 1598, LTD. (KY) 2019-01-17 — — US disclosed
US-20190016700-A1 METALLOENZYME INHIBITOR COMPOUNDS NQP 1598, LTD. (KY) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016700-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO CES2 286/4885CES1 198/4885ALDH1A1 289/4885
US-10464922-B2 Metalloenzyme inhibitor compounds MMEL1, GPX1, MPO CES2 286/4885CES1 198/4885ALDH1A1 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback